The RSI Indicator for SANA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 37 of the 42 cases the stock moved higher. This puts the odds of a move higher at 88%.
The Moving Average Convergence Divergence (MACD) for SANA just turned positive on October 26, 2026. Looking at past instances where SANA's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 54 cases where SANA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SANA as a result. In 71 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SANA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SANA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SANA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.532) is normal, around the industry mean (2.788). P/E Ratio (-3.120) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for XBI turned positive on October 21, 2026. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in 49 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 66 cases where XBI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
XBI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| SANA | XBI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 79% | 3 days ago 90% |
| Declines ODDS (%) | 5 days ago 89% | 5 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 87% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SANA’s FA Score shows that 1 FA rating(s) are green while .
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SANA’s TA Score shows that 3 TA indicator(s) are bullish.
SANA (@Biotechnology) experienced а -13.97% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.12%. For the same industry, the average monthly price growth was -4.39%, and the average quarterly price growth was -15.58%.
SANA is expected to report earnings on Mar 23, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with CRSP. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | -8.59% | ||
| CRSP - SANA | 59% Loosely correlated | -6.21% | ||
| EDIT - SANA | 59% Loosely correlated | -6.25% | ||
| RCKT - SANA | 57% Loosely correlated | -6.70% | ||
| BEAM - SANA | 57% Loosely correlated | -6.91% | ||
| MGTX - SANA | 55% Loosely correlated | -9.66% | ||
More | ||||
A.I.dvisor indicates that over the last year, XBI has been closely correlated with EDIT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if XBI jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To XBI | 1D Price Change % | ||
|---|---|---|---|---|
| XBI | 100% | -6.73% | ||
| EDIT - XBI | 69% Closely correlated | -6.25% | ||
| SANA - XBI | 66% Loosely correlated | -8.59% | ||
| SLDB - XBI | 65% Loosely correlated | -5.21% | ||
| IMVT - XBI | 65% Loosely correlated | -5.05% | ||
| DNLI - XBI | 65% Loosely correlated | -5.92% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBHH | 23.14 | -0.04 | -0.17% |
| iShares iBonds 2028 Term High Yield and Income ETF (IBHH) | |||
| GAEM | 25.49 | -0.12 | -0.47% |
| Simplify Gamma Emerging Market Bond ETF (GAEM) | |||
| DESK | 39.05 | -0.98 | -2.45% |
| VanEck Office and Commercial REIT ETF (DESK) | |||
| XSPI | 45.97 | -2.46 | -5.08% |
| NEOS Boosted S&P 500 High Income ETF (XSPI) | |||
| MUU | 12.62 | -6.61 | -34.37% |
| Direxion Daily MU Bull 2X ETF (MUU) | |||